Objective:To compare the therapy effects of chemotherapy and non-chemotherapy groups and to determine the value of chemotherapy for adult diffuse low-grade gliomas. Methods:We reviewed and analyzed 64 patients with adult diffuse low-grade glio-mas admitted to the Beijing Tiantan Hospital from May 2005 to April 2008. Among the patients, 18 received 4 to 12 cycles of temozolo-mide chemotherapy after operation and radiotherapy, whereas the other 46 cases only received radiotherapy. The progression-free survival of the two groups was compared. Results:The median progression-free survival of the chemotherapy and the control groups were 67.8 and 51.3 months, respectively. The results of the comparison implied a significant difference (χ2=8.741, P=0.003). Conclu-sion:Chemotherapy can improve the progression-free survival of the patients with adult diffuse low-grade gliomas, and thus, can be recommended as its effective therapy.

Objective To observe the expression of Caspase-12 and GRP78 of endoplasmic reticulum stress (ERS) in cardiac arrest and beating heart mitral valve replacement Methods Thirty patients with rheumatic heart disease mitral stenosis were randomly divided into beating heart group (BH,n=15) and cardiac arrest group(CA, n = 15). Both groups accepted MVR by beating heart surgery and cardiac arrest surgery under cardiopulmonary bypass (CPB) respectively. Right atrial myocardial tissues were collected at prior the start of CPB (T0), after aortic cross-clamping 30 minutes (BH group 30 minutes after CPB, T1) and stitched right atrium (T2) respectively. The method of reverse transcriptase polymerase chain reaction (RT-PCR) was applied to detect the expression level of Caspase-12 and GRP78 in two groups and positive staining of Caspase-12 and GRP78 of myocardial tissue slices in both groups was observed by immunohistochemical method. Results The expression of Caspase-12 in CA group heightened at T1and significantly increased at T2 (P < 0.05) but the expression of Caspase-12 in BH group had increased in T2 only (P < 0.05). Caspase-12 in CA group expressed higher than that in BH group at T1 and T2. The expression of GRP78 had increased at T1 in two groups but it in CA group expressed higher than that inBH group at T2. The number of positive staining of Caspase-12 and GRP78 in CA group was higher than that in BH group at T2. Conclusion MVR of beating heart can reduce the reaction of ERS to enhance the myocardial protection under CPB.

Objective To explore the effect of new therapy of high-dose methotrexate (HD-MTX,3 g/m2) combined with rituximab on primary central nervous system lymphoma.Methods Thirty-seven patients with primary central nervous system lymphoma,admitted to our hospital from January 2006 to January 2013,were chosen in our study; targeted therapy group (n=9) accepted chemotherapy scheme (HD-MTX +Rituximab 375 mg/m2) for 2-6 cycles (4 weeks a cycle),and the traditional treatment group adopted whole brain radiotherapy plus HD-MTX for 2-6 cycles.Progressive free survival (PFS) was compared between the two groups.Results Complete response was achieved in 5 patients of targeted therapy group,partial response in 2,stable disease in 1 and progressive disease in 1.Complete response was achieved in 12 patients of traditional treatment group,partial response in 11,stable disease in 4 and progressive disease in 2.The median PFS in the targeted therapy group was 28 months while that in the traditional treatment group was 11 months,with significant difference (R=0.823,P=0.021).Conclusion The scheme of HD-MTX combined with Rituximab for primary central nervous system lymphoma relieves the side-effect of the traditional therapy and gains satisfied results,which can be recommended as an effective therapy for primary central nervous system lymphoma.

Objective To compare with the therapy effect of bevacizumab or bevacizumab combined with dose-dense temozolomide on recurrent malignant gliomas.Methods Thirty-eight patients with recurrent malignant glioma,admitted to our hospital from June 2008 to June 2012,were chosen in our study.Among them,26 patients accepted bevacizumab therapy (single drug group) and 12 accepted bevacizumab combined with dose-dense temozolomide therapy (unite drugs group).Then,the clinical data,progressive free survival (PFS) and adverse effects were retrospectively analyzed.Results Single drug group:the median PFS was 21.8 weeks,PFS-6 months was 37.8％;united drug group:the median progressive free survival was 34.7 weeks,PFS-6 months was 52.7％;significant differences were noted between the two groups (x2=8.161,P=0.023) Conclusion Bevacizumab can prolong the PFS of patients with recurrent malignant glioma;the therapy effect of bevacizumab and dose-dense temozolomide is better than single drug,which can be recommended as an effective therapy for recurrent malignant glioma.

Objective:To construct and validate a prediction model combined machine learning with imaging omics characteristics in differentiating anaplastic glioma from glioblastoma.Methods:Imaging data of 241 patients with anaplastic glioma or glioblastoma, confirmed by pathology in our hospital from August 2005 to August 2012, were retrospectively collected. These patients were divided into a training group ( n=140) and a verification group ( n=101) according to random number table method. MRIcron software was used to delineate tumor boundaries of patients from the training group on preoperative T1 enhanced MR imaging. The regions of interest (ROIs) were outlined on preoperative T1 enhanced MR imaging, and the radiomic features were extracted from ROIs by Matlab software. Least absolute shrinkage and selection operator (LASSO) regression model was used to screen the features, and then, the selected features were used to construct the prediction model by support vector machine (SVM) classifier. The area under the curve (AUC) of receiver operating characteristic (ROC) curve was used to evaluate the predictive efficacy of the model. Results:In these 241 patients, 101 were with anaplastic glioma and 140 were with glioblastoma confirmed by pathology. In the training group and validation group, there was statistical difference in age between patients with anaplastic glioma and glioblastoma ( P<0.05); there was no significant difference in gender distribution, tumor location, and percentages of tumor necrosis or edema between patients with anaplastic glioma and glioblastoma ( P>0.05). Totally, 431 radiomic features were extracted; 11 radiomic features were screened by LASSO regression model and the prediction model was established. The AUC of ROC curve was 0.942 and 0.875, respectively, in the training group and validation group. Conclusion:The prediction model combined machine learning and imaging omics characteristics can effectively discriminate anaplastic glioma from glioblastoma.

OBJECTIVE: To train convolutional networks using multi-lead ECG data and classify new data accurately to provide reliable information for clinical diagnosis. METHODS: The data were pre-processed with a bandpass filter, and signal framing was adopted to adjust the data of different lengths to the same size to facilitate network training and prediction. The dataset was expanded by increasing the sample size to improve the detection rate of abnormal samples. A depth-wise separable convolution structure was used for more specific feature extraction for different channels of twelve-lead ECG data. We trained the two classifiers for each label using the improved DenseNet to classify different labels. RESULTS: The propose model showed an accuracy of 80.13% for distinguishing between normal and abnormal ECG with a sensitivity of 80.38%, a specificity of 79.91% and a F1 score of 79.35%. CONCLUSIONS The model proposed herein can rapidly and effectively classify the ECG data. The running time of a single dataset on GPU is 33.59 ms, which allows real-time prediction to meet the clinical requirements.
Algorithms ; Arrhythmias, Cardiac ; diagnosis ; Databases as Topic ; Electrocardiography ; classification ; methods ; Humans ; Neural Networks (Computer) ; Sensitivity and Specificity